Question 1

A patient with systemic lupus erythematosus (SLE) develops end-stage renal disease. Because of the underlying SLE, what treatment is recommended for this patient?&#10;A) Dialysis only&#10;B) Immunosuppressant therapy&#10;C) Kidney transplantation&#10;D) Palliative care

Accepted Answer

Kidney transplantation is the best option for a patient with SLE who has end-stage renal disease. This is because dialysis may not adequately control the disease activity of SLE, and immunosuppressant therapy may not be sufficient to prevent further damage to the kidneys. A successful kidney transplant can restore normal kidney function and improve the overall health of the patient. However, close monitoring and management of the SLE are necessary after transplantation to prevent rejection and recurrence of the disease. Palliative care is not the best option for a patient with end-stage renal disease and SLE, as kidney transplantation can significantly improve their quality of life.

Question 2

A patient with systemic lupus erythematosus (SLE) has frequent symptoms and has been taking prednisone for each episode. The provider plans to start hydroxychloroquine and the patient asks why this medication is necessary. What will the provider tell this patient about this medication?

A) It is effective in reducing disease flares and for tapering steroids.
B) It is given in conjunction with steroids to improve outcomes.
C) It lowers blood pressure and decreases the risk for renal disease.
D) It prevents the need for bisphosphonate therapy.

A

Accepted Answer

Hydroxychloroquine is an antimalarial medication that is commonly used to manage systemic lupus erythematosus (SLE). It is effective in reducing disease flares and for tapering steroids. It may also have other benefits, such as reducing the risk of cardiovascular events and improving skin and joint symptoms.

Question 3

Which laboratory tests may help distinguish systemic lupus erythematosus (SLE) from other systemic rheumatologic disorders?&#10;A) Antinuclear antibody titer&#10;B) C-reactive protein&#10;C) Rheumatoid factor&#10;D) Serum complement levels

Accepted Answer

D

Deck 199: Systemic Lupus Erythematosus